Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Thoracic 2Lymphoid 1Gastrointestinal 1

Conditions

Pleural Effusion, Malignant 1Lymphoma, Extranodal NK-T-Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × sugemalimab × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

NCT06617416 2025-03-12

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Akeso

Phase 3 Recruiting
560 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04194801 2023-02-06

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

CStone Pharmaceuticals

Phase 1/2 Completed
26 enrolled 31 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡